Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03203915 · ClinicalTrials.gov registry record · NA
Metabolic Response to Chardonnay Grape Marc Powder
A NA study, sponsored by USDA, Western Human Nutrition Research Center.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT03203915: Completed NA study, sponsored by USDA, Western Human Nutrition Research Center.
NCT03203915 is a NA study that has completed, run by USDA, Western Human Nutrition Research Center. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03203915, a NA study, has completed, sponsored by USDA, Western Human Nutrition Research Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
To determine if the addition of chardonnay grape marc (also called pomace) powder enriched with grape seed extract to the diet will result in reducing blood levels of cholesterol or triglycerides.
Primary Outcome
Fasting triglyceride concentrations, LDL cholesterol, HDL cholesterol, non-HDL cholesterol will be measured in serum; postprandial triglyceride measurements (1, 2, 3 hours)
Interventions
- DIETARY_SUPPLEMENT Chardonnay grape marc marc high polyphenol dose (120mg)
- DIETARY_SUPPLEMENT Chardonnay grape marc powder low polyphenol dose (75mg)
- DIETARY_SUPPLEMENT Placebo (0mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2019-06-28 |
| Phase | NA |
What the finished NCT03203915 record still lists
NCT03203915 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Chardonnay grape marc marc high polyphenol dose (120mg) is the first listed.
NCT03203915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03203915 about?
NCT03203915 is a clinical study titled "Metabolic Response to Chardonnay Grape Marc Powder". To determine if the addition of chardonnay grape marc (also called pomace) powder enriched with grape seed extract to the diet will result in reducing blood levels of cholesterol or triglycerides.
What is the current status of trial NCT03203915?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2017-08-01. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT03203915?
The interventions under investigation include: Chardonnay grape marc marc high polyphenol dose (120mg) (DIETARY_SUPPLEMENT), Chardonnay grape marc powder low polyphenol dose (75mg) (DIETARY_SUPPLEMENT), Placebo (0mg) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03203915?
This trial is sponsored by USDA, Western Human Nutrition Research Center, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03203915's enrollment target sits among peer trials
31 1592nd of 2000 higher than 408 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI